Regulus Therapeutics Inc. (RGLS)

NASDAQ: RGLS · IEX Real-Time Price · USD

1.760

-0.140 (-7.37%)

At close: Jul 2, 2024, 4:00 PM

1.750

-0.010 (-0.57%)

After-hours: Jul 2, 2024, 7:42 PM EDT

Regulus Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2010
Revenue	0	0	0	10.01	6.83	Upgrade
Revenue Growth (YoY)	-	-	-	46.46%	9388.89%	Upgrade
Gross Profit	0	0	0	10.01	6.83	Upgrade
Selling, General & Admin	9.96	9.83	10.02	8.81	11.32	Upgrade
Research & Development	21.15	18.41	17.79	15.35	12.35	Upgrade
Operating Expenses	31.11	28.24	27.82	24.16	23.67	Upgrade
Operating Income	-31.11	-28.24	-27.82	-14.16	-16.83	Upgrade
Interest Expense / Income	0.6	0.69	0.86	1.81	2.13	Upgrade
Other Expense / Income	-1.68	-0.61	-0.86	-0.23	-0.37	Upgrade
Pretax Income	-30.04	-28.32	-27.81	-15.73	-18.59	Upgrade
Income Tax	0	0	0	0	0	Upgrade
Net Income	-30.04	-28.32	-27.81	-15.73	-18.59	Upgrade
Shares Outstanding (Basic)	19	15	9	3	2	Upgrade
Shares Outstanding (Diluted)	19	15	9	3	2	Upgrade
Shares Change	24.25%	78.07%	145.01%	102.65%	97.97%	Upgrade
EPS (Basic)	-1.58	-1.86	-3.24	-4.50	-10.80	Upgrade
EPS (Diluted)	-1.58	-1.86	-3.24	-4.50	-10.80	Upgrade
Free Cash Flow	-27.38	-25.89	-24.38	-12.54	-19.72	Upgrade
Free Cash Flow Per Share	-1.44	-1.70	-2.85	-3.58	-11.43	Upgrade
Gross Margin	-	-	-	100.00%	100.00%	Upgrade
Operating Margin	-	-	-	-141.47%	-246.40%	Upgrade
Profit Margin	-	-	-	-157.21%	-272.13%	Upgrade
Free Cash Flow Margin	-	-	-	-125.28%	-288.70%	Upgrade
EBITDA	-29.21	-27.51	-26.49	-13.46	-15.53	Upgrade
EBITDA Margin	-	-	-	-134.47%	-227.30%	Upgrade
Depreciation & Amortization	0.23	0.12	0.46	0.47	0.93	Upgrade
EBIT	-29.43	-27.63	-26.95	-13.92	-16.46	Upgrade
EBIT Margin	-	-	-	-139.14%	-240.93%	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).